NEW YORK (GenomeWeb) – Nanion Technologies and Axion Biosystems today announced a distribution deal covering Europe and China.
Under the terms of the agreement, Nanion will immediately distribute, service, and support Axion's single-well microelectrode array system called the Muse, as well as the Maestro system, a multiwall MEA system with high-throughput screening capabilities. The deal comes amid growing demand for "disease-in-a-dish" assays and functional safety screening, the companies said.
Nanion CEO Niels Fertig said in a statement that Axion's products are "an excellent complement to our automated patch clamp screening and impedance-based systems, and [we] see great potential for applications, including phenotype screening, stem cells as tools for phenotypic disease models, and of course, safety, neuro- and cardiotoxicity testing."
Financial and other terms of the deal were not disclosed.